Tag: Infliximab

1. Carriage of the HLA-DQA1*05 allele is significantly associated with the development of antibodies against anti-TNF agents. Evidence Rating Level: 2 (Good) Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologics for treating immune-mediated diseases. However, repeated administration can lead to the formation of anti-drug antibodies (immunogenicity), which can...
In patients with Crohn’s disease (CD), endoscopic evidence of healing after treatment is associated with favorable outcomes. Anti-tumor necrosis factor (TNF) agents have been shown to induce ileocolonic healing in CD, however the impact of these agents on gross small bowel healing as indicated by endoscopy has not been...
Depressive symptoms are an important part of bipolar disorder types I/II and contribute to significant morbidity and mortality. Establishing treatments for bipolar disorder has been difficult; in fact, no existing treatments approved by the FDA have been developed using an a priori disease model, and multiple failed clinical trials...
Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography Both multifocal motor neuropathy (MMN) and amyotrophic lateral sclerosis (ALS) affect the peripheral nervous system and present with palsies. Differentiating between these two diseases is important from a prognostic perspective, as MMN should be treated as early as possible...
Anti-tumor necrosis factor (TNF) therapies are commonly used in the treatment of patients with moderate to severe Crohn’s disease. However, due to the high costs of anti-TNF medications, biosimilar medications are being developed. These drugs have high likeness to already licensed biological therapies and are subject to strict approval...
Outcomes of Extremely Preterm Infants With Birth Weight Less Than 400 g Little is known about the survival and neurodevelopmental outcomes of extremely preterm infants with low birth weight. More data is needed to facilitate decisions regarding the initiation of treatment and resuscitation in this population. In this retrospective cohort...
1. The biosimilar to infliximab, CT-P13 was shown in this study to have equivalent efficacy to the anti tumor-necrosis factor (TNF) monoclonal antibody for Crohn’s treatment. 2. There was no significant safety differences observed in this study between the two treatments for Crohn’s disease. Evidence Rating Level: 2 (Good) Study Rundown: Crohn’s...
1. From a retrospective single center cohort study, 29% of patients taking anti-TNF therapy for inflammatory bowel disease developed skin manifestations, most often psoriasiform eczema and eczema. 2. Of those who developed skin manifestations, 10.6% stopped therapy because of the skin lesions, and most lesions resolved upon discontinuation of therapy. Evidence...
Image: PD 1. The severity of Crohn’s disease as assessed by the Pediatric Crohn’s Disease Activity Index in patients recruited from 3 pediatric specialty centers decreased significantly over the course of a 12-week treatment regimen with infliximab. 2. All patients were on corticosteroids at the start of the study; however, steroid...